TABLE 1 Characteristics of included RCTs in the meta-analysis1 TABLE 1 Characteristics of included RCTs in the meta-analysis1 TABLE 1 Characteristics of included RCTs in the meta-analysis1 TABLE 1 Characteristics of included RCTs in the meta-analysis1 TABLE 1 Characteristics of included RCTs in the meta-analysis1 TABLE 1 Characteristics of included RCTs in the meta-analysis1 TABLE 1 Characteristics of included RCTs in the meta-analysis1 TABLE 1 Characteristics of included RCTs in the meta-analysis1 TABLE 1 Characteristics of included RCTs in the meta-analysis1 TABLE 1 Characteristics of included RCTs in the meta-analysis1 TABLE 1 Characteristics of included RCTs in the meta-analysis1
Study, year
country
design
Subjects, n, T/C
gender
Mean age years
Underline diseases
Study duration days
Type of intervention in intervention group
Type of intervention in control group
Outcome measured
(Elamin et al., 2012), USA Parallel 11/11 M/F 53.3 Medical- Surgical Patients with ARDS 7 Oxepa® Ross Labs, Chicago, Illinois, USA Pulmocare® Ross Labs, Chicago, Illinois, USA Duration of ICU stay, level of oxygenation, duration of mechanical ventilation, SOFA and MOD score, 28 days mortality
(Gadek et al., 1999) USA Parallel 45/43 M/F 63 ARDS patients 7 The lipid blend provides EPA and docosahexaenoic acid from fish oil and GLA from borage oil high-fat, low-carbohydrate enteral nutrition formula Duration of ICU stay, level of oxygenation, duration of mechanical ventilation, length of hospital stay, ventilator free days, ICU free days, 28 days mortality
(Grau-Carmona et al., 2011) Spain Parallel 61/71 M/F 63.5 Septic patients with ALI or ARDS 21 Oxepa Abbott Labs Ensur Abbott Labs Duration of ICU stay, level of oxygenation, duration of mechanical ventilation, 28 days mortality
(Kagan et al., 2015) Israel Parallel 62/58 M/F 40.72 severe multiple trauma 8 Oxepa; Ross Laboratories Pulmocare; Ross laboratories, Chicago, IL Duration of ICU stay, level of oxygenation, duration of mechanical ventilation, length of hospital stay, SOFA and MOD score, 28 days mortality
(Pontes-Arruda et al., 2011) Brazil Parallel 53/53 M/F 71 Early sepsis 7 EPA/GLA diet isocaloric, isonitrogenous control diet Duration of ICU stay, duration of mechanical ventilation, length of hospital stay, ICU free days, SOFA and MOD score, 28 days mortality
(Pontes-Arruda et al., 2006) Brazil Parallel 55/48 M/F 66.1 ventilated patients with severe sepsis and septic shock 7 enteral nutrition enriched with EPA, GLA, isonitrogenous and isocaloric control diet level of oxygenation, ICU free days, ventilator free days, 28 days mortality
(Rice et al., 2011) USA Parallel 143/129 M/F 59 ALI patients 28 enteral supple- mentation of n-3 fatty acids, GLA, and antioxidants isocaloric-isovolemic carbohydrate-rich control Duration of ICU stay, ICU free days, ventilator free days, 28 days mortality
(Shirai et al., 2015) Japan Parallel 23/23 M/F 72.5 sepsis-induced ARDS 14 Oxepa™; Abbott Nutrition, Tokyo, Japan Ensure Liquid™; Abbott Nutrition, Tokyo, Japan Duration of ICU stay, level of oxygenation, duration of mechanical ventilation, ICU free days, ventilator free days, SOFA and MOD score, 28 days mortality
(Singer et al., 2006) Israel Parallel 44/44 M/F 59.6 ventilated patients with ALI 14 Oxepa, Ross Laboratories high-fat, low-carbohydrate, enteral formula (Pulmo- care, Ross Laboratories, Chicago, IL) level of oxygenation, duration of mechanical ventilation, length of hospital stay, 28 days mortality
(Tsukahara et al., 2014) Japan Parallel 30/32 M/F 63.8 Head and Neck Cancer Surgery Patients 8 Oxepa®; Abbott Japan Ensure® H; Abbott Japan, Tokyo, Japan Duration of ICU stay, length of hospital stay,
1RCTs, randomized controlled trials; Duration refers to the duration of treatment. T/C, treatment/control. M, male; F, female; ARDS, acute respiratory distress syndrome; ALI , acute lung injury; ICU, intensive care unit; SOFA, sequential organ failure assessment; MOD, multiple organ disfunction 1RCTs, randomized controlled trials; Duration refers to the duration of treatment. T/C, treatment/control. M, male; F, female; ARDS, acute respiratory distress syndrome; ALI , acute lung injury; ICU, intensive care unit; SOFA, sequential organ failure assessment; MOD, multiple organ disfunction 1RCTs, randomized controlled trials; Duration refers to the duration of treatment. T/C, treatment/control. M, male; F, female; ARDS, acute respiratory distress syndrome; ALI , acute lung injury; ICU, intensive care unit; SOFA, sequential organ failure assessment; MOD, multiple organ disfunction 1RCTs, randomized controlled trials; Duration refers to the duration of treatment. T/C, treatment/control. M, male; F, female; ARDS, acute respiratory distress syndrome; ALI , acute lung injury; ICU, intensive care unit; SOFA, sequential organ failure assessment; MOD, multiple organ disfunction 1RCTs, randomized controlled trials; Duration refers to the duration of treatment. T/C, treatment/control. M, male; F, female; ARDS, acute respiratory distress syndrome; ALI , acute lung injury; ICU, intensive care unit; SOFA, sequential organ failure assessment; MOD, multiple organ disfunction 1RCTs, randomized controlled trials; Duration refers to the duration of treatment. T/C, treatment/control. M, male; F, female; ARDS, acute respiratory distress syndrome; ALI , acute lung injury; ICU, intensive care unit; SOFA, sequential organ failure assessment; MOD, multiple organ disfunction 1RCTs, randomized controlled trials; Duration refers to the duration of treatment. T/C, treatment/control. M, male; F, female; ARDS, acute respiratory distress syndrome; ALI , acute lung injury; ICU, intensive care unit; SOFA, sequential organ failure assessment; MOD, multiple organ disfunction 1RCTs, randomized controlled trials; Duration refers to the duration of treatment. T/C, treatment/control. M, male; F, female; ARDS, acute respiratory distress syndrome; ALI , acute lung injury; ICU, intensive care unit; SOFA, sequential organ failure assessment; MOD, multiple organ disfunction 1RCTs, randomized controlled trials; Duration refers to the duration of treatment. T/C, treatment/control. M, male; F, female; ARDS, acute respiratory distress syndrome; ALI , acute lung injury; ICU, intensive care unit; SOFA, sequential organ failure assessment; MOD, multiple organ disfunction 1RCTs, randomized controlled trials; Duration refers to the duration of treatment. T/C, treatment/control. M, male; F, female; ARDS, acute respiratory distress syndrome; ALI , acute lung injury; ICU, intensive care unit; SOFA, sequential organ failure assessment; MOD, multiple organ disfunction 1RCTs, randomized controlled trials; Duration refers to the duration of treatment. T/C, treatment/control. M, male; F, female; ARDS, acute respiratory distress syndrome; ALI , acute lung injury; ICU, intensive care unit; SOFA, sequential organ failure assessment; MOD, multiple organ disfunction